Thomas Czypionka together with colleagues from the University of Rome Tor Vergata, the Andalusian School of Public Health, Kingston University London and the IMIM Barcelona, published a paper on Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections.